BNF:

1.5

Status:

Amber

Decision Date:

None

Comments

See shared care guideline for immunomodulating drugs

Sulfasalazine plain tabs are licensed to treat ulcerative colitis and crohn's disease. 

Sulfasalazine EC tabs are licensed  to treat ulcerative colitis, crohn's disease and rheumatoid arthritis. 

Salazopyrin is the preferred cost-effective brand. (Decision date - April 2023)

Amber Drug Classifications

• 1: Requiring specialist assessment to enable patient selection and initiation of treatment
• 2: Requiring short or medium term (e.g. 3-6 months) specialist monitoring of efficacy or until the patient is stable

search again